Top

Indian Journal of Otolaryngology and Head & Neck Surgery

Published in:

18-06-2020 | Rhinosinusitis | Other Articles

Eosinophilic Otitis Media: Modern Aspects of Pathogenesis, Clinical Features, Diagnosis and Treatment

Authors: Elena Shevchik, Valery Svistushkin, Galina Nikiforova, Anna Zolotova

Published in: Indian Journal of Otolaryngology and Head & Neck Surgery | Special Issue 1/2022

Abstract

Eosinophilic otitis media (EOM) is an inflammatory chronic disease of the middle ear, characterized by the presence of a particularly viscous effusion with a high content of protein toxins of eosinophilic origin in the middle ear cavity. The pathology has relationship with bronchial asthma, allergic rhinitis and chronic rhinosinusitis with nasal polyps. EOM is characterized by a sluggish course, a tendency to relapse, which can lead to a gradual hearing decrease up to complete deafness. In this paper, we reviewed the international literature with special attention to pathogenesis and treatment management.

Koch H (1947) Allergical investigations of chronic otitis. Acta Otolaryngol 62(Suppl.):1–201

Tomioka S, Yuasa R, lino Y (1994) Intractable otitis media in cases with bronchial asthma. Recent advances in otitis media with effusion. In: Proceedings of the second extraordinary international symposium on recent advances on otitis media. Kugler Publications, Inc., Amsterdam, pp 183–186

Suzuki H, Matsutani S, Kawase T, Iino Y, Kawauchi H, Gyo K et al (2004) Epidemiologic surveillance of ‘‘eosinophilic otitis media’’ in Japan. Otol Jpn 14:112–117 (In Japanese)

Grossman J (1997) One airway, one disease. Chest 111(2 Suppl):11S–16S. https://doi.org/10.1378/chest.111.2_supplement.11sCrossRefPubMed

Azadarmaki R, Westra W, Prasad S (2015) Eosinophilic Mucin otomastoiditis and otopolyposis: a progressive form of eosinophilic otitis media. Ann Otol Rhinol Laryngol 124(9):752–756. https://doi.org/10.1177/0003489415577988CrossRefPubMed

Neff BA, Voss SG, Carlson ML, O’Brien EK, Butterfield JH (2017) Treatment of eosinophilic otitis media with pegylated interferonalpha 2a and 2b. Laryngoscope 127:1208–1216CrossRef

Lara-Sánchez H, Vallejo L (2017) Eosinophilic otitis media. N Engl J Med 376(7):e10. https://doi.org/10.1056/NEJMicm1510852CrossRefPubMed

Chow K, Cosetti M (2020) Use of IL-5 inhibitor benralizumab as a novel therapy for eosinophilic otitis media. Otol Neurotol 41(2):e238–e240. https://doi.org/10.1097/MAO.0000000000002493CrossRefPubMed

Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M (2011) Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx 38:456–461CrossRef

10.

Omori M, Ziegler S (2007) Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin. J Immunol 178(3):1396–1404. https://doi.org/10.4049/jimmunol.178.3.1396CrossRefPubMed

11.

Simson L, Foster PS (2000) Chemokine and cytokine cooperativity: eosinophil migration in the asthmatic response. Immunol Cell Biol 78(4):415–422. https://doi.org/10.1046/j.1440-1711.2000.00922.xCrossRefPubMed

12.

Yao T, Kojima Y, Koyanagi A et al (2009) Eotaxin-1, -2, and -3 immunoreactivity and protein concentration in the nasal polyps of eosinophilic chronic rhinosinusitis patients. Laryngoscope 119(6):1053–1059. https://doi.org/10.1002/lary.20191CrossRefPubMed

13.

Ueki S, Konno Y, Takeda M, Moritoki Y, Hirokawa M, Matsuwaki Y, Honda K, Ohta N, Yamamoto S, Takagi Y, Wada A, Weller PF (2016) Eosinophil extracellular trap cell death-derived DNA traps: their presence in secretions and functional attributes. J Allergy Clin Immunol 137(1):258–267. https://doi.org/10.1016/j.jaci.2015.04.041Epub 2015 Jun 9CrossRefPubMed

14.

IinoY Kakizaki K, Saruya S, Katano H, Komiya T, Kodera K et al (2006) Eustachian tube function in patients with eosinophilic otitis media associated with bronchial asthma evaluated by sonotubometry. Arch Otolaryngol Head Neck Surg 132:1109–1114CrossRef

15.

Kanazawa H, Yoshida N, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A et al (2013) Risk factors for eosinophilic otitis media in patients with eosinophilic chronic rhinosinusitis. Int Adv Otol 9:353–358

16.

Iino Y (2010) Role of IgE in eosinophilic otitis media. Allergol Int 59:233–238. https://doi.org/10.2332/allergolint.10-RAI-0223CrossRefPubMed

17.

Ohta N, Ueki S, Konno Y, Hirokawa M, Kubota T, Tomioka-Matsutani S, Suzuki T, Ishida Y, Kawano T, Miyasaka T, Takahashi T, Suzuki T, Ohno I, Kakehata S, Fujieda S (2018) ETosis-derived DNA trap production in middle ear effusion is a common feature of eosinophilic otitis media. Allergol Int 67(3):414–416. https://doi.org/10.1016/j.alit.2017.11.007CrossRefPubMed

18.

Ueki S, Ohta N, Takeda M, Konno Y, Hirokawa M (2017) Eosinophilic otitis media: the aftermath of eosinophil extracellular trap cell death. Curr Allergy Asthma Rep 17(5):33. https://doi.org/10.1007/s11882-017-0702-5CrossRefPubMed

19.

Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A (2010) Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 191(3):677–691. https://doi.org/10.1083/jcb.201006052CrossRefPubMedPubMedCentral

20.

Uchimizu H, Matsuwaki Y, Kato M, Otori N, Kojima H (2015) Eosinophil-derived neurotoxin, elastase, and cytokine profile in effusion from eosinophilic otitis media. Allergol Int 64(Suppl):S18–S23. https://doi.org/10.1016/j.alit.2015.03.007Epub 2015 Apr 25CrossRefPubMed

21.

Miura T, Matsubara A, Kudo N, Hara R, Takahata J, Sasaki A (2018) The expression of thymic stromal lymphopoietin in patients and animal models with eosinophilic otitis media. Acta Otolaryngol 138(5):447–451. https://doi.org/10.1080/00016489.2017.1416170CrossRefPubMed

22.

Nonaka M, Fukumoto A, Ozu C, Mokuno E, Baba S, Pawankar R et al (2003) IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. Acta Otolaryngol 123:383–387CrossRef

23.

Iino Y, Kakizaki K, Katano H, Saigusa H, Kanegasaki S (2005) Eosinophil chemoattractant in middle ear patients with eosinophilic otitis media. Clin Exp Allergy 35:1370–1376CrossRef

24.

Iino Y, Nagamine H, Yabe T, Matsutani S (2001) Eosinophils are activated in middle ear mucosa and middle ear effusion of patients with intractable otitis media associated with bronchial asthma. Clin Exp Allergy 31:1135–1143CrossRef

25.

Matsubara A, Nishizawa H, Kurose A, Nakagawa T, Takahata J, Sasaki A (2014) An experimental study of inner ear injury in an animal model of eosinophilic otitis media. Acta Otolaryngol 134(3):227–232. https://doi.org/10.3109/00016489.2013.859395(Epub 2013 Dec 23)CrossRefPubMed

26.

Kudo N, Matsubara A, Nishizawa H, Miura T (2017) Immunohistological analysis of eotaxin and RANTES in the model animal of eosinophilic otitis media. Acta Otolaryngol 137(5):476–481. https://doi.org/10.1080/00016489.2016.1266508(Epub 2016 Dec 16)CrossRefPubMed

27.

Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S et al (2006) Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13-signals. J Allergy Clin Immunol 118:98–104CrossRef

28.

Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K et al (2011) Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 5:1119–1127CrossRef

29.

Nishizawa H, Matsubara A, Nakagawa T, Ohta N, Izuhara K, Shirasaki T, Abe T, Takeda I, Shinkawa H (2012) The role of periostin in eosinophilic otitis media. Acta Otolaryngol 132(8):838–844. https://doi.org/10.3109/00016489.2012.668708Epub 2012 Jun 5CrossRefPubMed

30.

Iino Y (2008) Eosinophilic otitis media: a new middle ear disease entity. Curr Allergy Asthma Rep 8(6):525–530CrossRef

31.

Kanazawa H, Yoshida N, Yamamoto H, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Iino Y (2014) Risk factors associated with severity of eosinophilic otitis media. Auris Nasus Larynx 41(6):513–517. https://doi.org/10.1016/j.anl.2014.08.003CrossRefPubMed

32.

Tanaka Yukako, Nonaka Manabu, Yamamura Yukie, Tagaya Etsuko, Pawankar Ruby, Yoshihara Toshio (2013) Improvement of eosinophilic otitis media by optimized asthma treatment. Allergy Asthma Immunol Res 5(3):175–178CrossRef

33.

Seo Yukako, Nonaka Manabu, Yamamura Yukie (2018) Optimal control of asthma improved eosinophilic otitis media. Asia Pacific Allergy 8(1):e5CrossRef

34.

Chung WJ, Lee JH, Lim HK, Yoon TH, Cho KJ, Baek JH (2012) Eosinophilic otitis media: CT and MRI findings and literature review. Korean J Radiol 13(3):363–367. https://doi.org/10.3348/kjr.2012.13.3.363CrossRefPubMedPubMedCentral

35.

Saliba I, Alzahrani M, Weng X, Bestavros A (2017) Eosinophilic otitis media diagnosis using flow cytometric immunophenotyping. Acta Oto-Laryngol. https://doi.org/10.1080/00016489.2017.1385845CrossRef

36.

Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100CrossRef

37.

Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192CrossRef

38.

Harabuchi Yasuaki, Kishibe Kan, Tateyama Kaori, Morita Yuka, Yoshida Naohiro, Kunimoto Yasuomi, Matsui Takamichi, Sakaguchi Hiroshi, Okada Masahiro, Watanabe Takeshi, Inagaki Akira, Kobayashi Shigeto, Iino Yukiko, Murakami Shingo, Takahashi Haruo, Tono Tetsuya (2017) Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): a retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol 27(1):87–94. https://doi.org/10.1080/14397595.2016.1177926CrossRefPubMed

39.

Ishiyama A, Canalis RF (2001) Otological manifestations of Churg–Strauss syndrome. Laryngoscope 111(9):1619–1624. https://doi.org/10.1097/00005537-200109000-00024CrossRefPubMed

40.

Martinez Del Pero M, Moffat D, Sudhoff H (2008) Unusual presentation of temporal bone involvement in Churg–Strauss syndrome. J Laryngol Otol 122:425–427CrossRef

41.

Seccia V, Fortunato S, Cristofani-Mencacci L et al (2016) Focus on audiologic impairment in eosinophilic granulomatosis with polyangiitis. Laryngoscope 126(12):2792–2797. https://doi.org/10.1002/lary.25964CrossRefPubMed

42.

Ovadia S, Dror I, Zubkov T, Tanay A, Levy D, Zandman-Goddard G (2009) Churg–Strauss syndrome: a rare presentation with otological and pericardial manifestations: case report and review of the literature. Clin Rheumatol 28(Suppl. 1):S35–S38CrossRef

43.

Groh M, Pagnoux C, Baldini C et al (2015) Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26:545–553CrossRef

44.

Fukuda A, Morita S, Nakamaru Y, Hoshino K, Fujiwara K, Homma A (2019) Differentiation between eosinophilic otitis media and otitis media associated with eosinophilic granulomatosis with polyangiitis. Otol Neurotol 40(8):e796–e802. https://doi.org/10.1097/MAO.0000000000002295CrossRefPubMed

45.

Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 54(1):1–27. https://doi.org/10.1097/00005792-197501000-00001CrossRefPubMed

46.

Takayama K, Yadohisa O, Furuno T, Hashimoto S, Nakanishi Y, Abe M et al (1995) Case report: the first report of idiopathic hypereosinophilic syndrome involved with lung and middle ear. Am J Med Sci 309:282–284PubMed

47.

Reiter A, Gotlib J (2017) Myeloid neoplasms with eosinophilia. Blood 129(6):704–714. https://doi.org/10.1182/blood-2016-10-695973CrossRefPubMed

48.

Longmore M, Wilkinson I, Turmezei T, Cheung CK (2007). Oxford handbook of clinical medicine. Oxford. p 316. ISBN:978-0-19-856837-7

49.

Iino Y, Nagamine H, Kakizaki K, Komiya T, Katano H, Saruya S et al (2006) Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis mediaassociated with bronchial asthma. Ann Allergy Asthma Immunol 97:761–766CrossRef

50.

Iino Y, Nagamine H, Kakizaki K et al (2006) Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma. Ann Allergy Asthma Immunol 97(6):761–766. https://doi.org/10.1016/S1081-1206(10)60967-2CrossRefPubMed

51.

Matsubara A, Kuroda R, Usami S, Takahata J, Shinkawa H (2001) The effect of topical administration of heparin to the eosinophilic otitis media. In: Takasaka T, Yuasa R, Hozawa K (eds) Recent advances in otitis media. Bologna: Monduzzi Editore, pp 403–406

52.

Esu Y, Iino Y, Masuda M, Kanazawa H, Yoshida N (2018) Proposal of a treatment strategy for eosinophilic otitis media based on middle ear condition. Otol Neurotol 39(8):e671–e678. https://doi.org/10.1097/MAO.0000000000001912CrossRefPubMed

53.

Okude A, Tagaya E, Kondo M, Nonaka M, Tamaoki J (2012) A case of severe asthma with eosinophilic otitis media successfully treated with anti-IgE monoclonal antibody omalizumab. Case Rep Pulmonol 2012:340525PubMedPubMedCentral

54.

Smith KA, Pulsipher A, Gabrielsen DA, Alt JA (2018) Biologics in chronic rhinosinusitis: an update and thoughts for future directions. Am J Rhinol Allergy 32:412–423CrossRef

55.

FDA approves first treatment for chronic rhinosinusitis with nasal polyps [news release]. Silver Spring, MD: Food and Drug Administration Office of Media Affairs; 2019. Avaliable at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatmentchronic-rhinosinusitis-nasal-polyps. Accessed July 2 2019

56.

Iino Y, Takahashi E, Ida S, Kikuchi S (2019) Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media. Auris Nasus Larynx 46(196–203):15

57.

Iino Y, Hara M, Hasegawa M et al (2012) Clinical efficacy of anti-IgE therapy for eosinophilic otitis media. Otol Neurotol 33:1218–1224CrossRef

58.

Iino Y, Hara M, Hasegawa M et al (2014) Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media. Acta Otolaryngol 134(4):366–372. https://doi.org/10.3109/00016489.2013.868601CrossRefPubMed

59.

El-Qutob D (2016) Off-label uses of omalizumab. Clinic Rev Allerg Immunol 50:84–96. https://doi.org/10.1007/s12016-015-8490-yCrossRef

60.

Markham A (2018) Benralizumab: first global approval. Drugs 78:505–511. https://doi.org/10.1007/s40265-018-0876-8CrossRefPubMed

61.

Wada T, Uemaetomari I, Murashita H et al (2006) Successful treatment of eosinophilic otitis media using ramatroban: report of two cases. Auris Nasus Larynx 33(4):455–460. https://doi.org/10.1016/j.anl.2006.05.007CrossRefPubMed

62.

Iino Y, Usubuchi H, Kodama K et al (2010) Eosinophilic inflammation in the middle ear induces deterioration of bone-conduction hearing level in patients with eosinophilic otitis media. Otol Neurotol 31:100–104CrossRef

63.

Iwasaki S, Nagura M, Mizuta K (2006) Cochlear implantation in a patient with eosinophilic otitis media. Eur Arch Otorhinolaryngol 263:365–369. https://doi.org/10.1007/s00405-005-1006-2CrossRefPubMed

64.

Sugimoto H, Hatano M, Noda M et al (2017) Cochlear implantation in deaf patients with eosinophilic otitis media using subtotal petrosectomy and mastoid obliteration. Eur Arch Otorhinolaryngol 274:1173–1177. https://doi.org/10.1007/s00405-016-4091-5CrossRefPubMed

Title: Eosinophilic Otitis Media: Modern Aspects of Pathogenesis, Clinical Features, Diagnosis and Treatment
Authors: Elena Shevchik
Valery Svistushkin
Galina Nikiforova
Anna Zolotova
Publication date: 18-06-2020
Publisher: Springer India
Keywords: Rhinosinusitis
Bronchial Asthma
Published in: Indian Journal of Otolaryngology and Head & Neck Surgery / Issue Special Issue 1/2022
Print ISSN: 2231-3796
Electronic ISSN: 0973-7707
DOI: https://doi.org/10.1007/s12070-020-01903-z

2024 ASCO Annual Meeting

Springer Medicine

Eosinophilic Otitis Media: Modern Aspects of Pathogenesis, Clinical Features, Diagnosis and Treatment

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2022

Changing Scenario in Tympanoplasty: Endoscopic Versus Microscopic Approach

The Role of Video Head Impulse Test (Vhit) in Diagnosing Benign Paroxysmal Positional Vertigo (BPPV)

Study of the Reliability of High Resolution CT Scan Evaluation of Eustachian Tube as Predictor of Predisposition for Chronic Otitis Media

A Simple Technique to Obliterate Canal Wall Down Mastoid Cavity Concurrently in Squamosal Otitis Media: Our Experience

Effects of ‘Perinatal Risk Factors Associated with Hearing Loss’ on Auditory Outcomes in Cochlear Implant Recipient Children

Influence of Personality and Attitude Towards Loss of Hearing on Hearing Aid Outcome in Older Adults with Hearing Loss